Literature DB >> 17185968

Ethanol versus radiofrequency ablation for the treatment of small hepatocellular carcinoma in patients with cirrhosis: a retrospective study of efficacy and cost.

Olivier Seror1, Gisèle N'Kontchou, Myint Tin Tin Htar, Isabelle Durand-Zaleski, Jean Claude Trinchet, Nicolas Sellier, Michel Beaugrand.   

Abstract

OBJECTIVE: To compare cost effectiveness of radio-frequency (RF) ablation versus percutaneous ethanol (Pe) ablation for treatment of small hepatocellular carcinoma.
METHODS: 57 patients with 72 hepatocellular carcinomas (HCC) treated with ethanol ablation were retrospectively compared with 60 new patients who had 72 HCC treated with RF ablation. All patients had Child-Pugh A cirrhosis and HCC less than 3.5 cm in diameter. Therapeutic efficacy was evaluated with tri-phase spiral computed tomography. Cost of hospital stay, supplies and follow-up including complications were calculated. Survival was estimated by Kaplan-Meier method and prognostic value of treatment methods by Log Rank test and multivariate Cox proportional hazard model.
RESULTS: The two groups had similar baseline characteristics. The rate of severe complications associated with RF was 15% (9/60) vs 6,9% (9/60) with Pe (P=0,11) The two-year overall survival, disease free survival and local tumor free survival in the ethanol and radiofrequency groups were 70.8% vs. 91.2% (Odd Ratio=3.7, P=0.006), 48.6% vs. 71.1% (Odd Ratio=2.2, P=0.01), and 68.5% vs. 80.7%, (Odd Ratio=1.9; P=0.09), respectively. The treatment method was the sole significant factor related to overall and tumor free survival. Costs per patient of ethanol and radiofrequency treatments were 1534 euro and 1196 euro, respectively.
CONCLUSION: This retrospective study suggests that RF is the most cost effective strategy, with higher 2-year disease free survival rate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17185968     DOI: 10.1016/s0399-8320(06)73534-5

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  7 in total

1.  Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors.

Authors:  Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

2.  Power Doppler ultrasonography with time-signal intensity curves in monitoring hepatocellular carcinoma and liver metastases after intralesional therapy.

Authors:  R Farina; F Pennisi; G Mazzone; M Pennisi; G Riva; P V Foti; C Puglisi; G C Ettorre
Journal:  Radiol Med       Date:  2008-09-26       Impact factor: 3.469

Review 3.  Use of antibodies and immunoconjugates for the therapy of more accessible cancers.

Authors:  Robert M Sharkey; David M Goldenberg
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

4.  Recent advances in radiofrequency ablation for the management of hepatocellular carcinoma.

Authors:  Takashi Himoto; Kazutaka Kurokohchi; Seishiro Watanabe; Tsutomu Masaki
Journal:  Hepat Mon       Date:  2012-10-10       Impact factor: 0.660

Review 5.  A review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis.

Authors:  Tan To Cheung; Ka Wing Ma; Wong Hoi She
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 8.265

Review 6.  Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis.

Authors:  Wen Luo; Yunfei Zhang; Guangbin He; Ming Yu; Minjuan Zheng; Liwen Liu; Xiaodong Zhou
Journal:  World J Surg Oncol       Date:  2017-07-10       Impact factor: 2.754

7.  Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study.

Authors:  Fabio Farinati; Adriana Sergio; Anna Baldan; Anna Giacomin; Maria Anna Di Nolfo; Paolo Del Poggio; Luisa Benvegnu; Gianludovico Rapaccini; Marco Zoli; Franco Borzio; Edoardo G Giannini; Eugenio Caturelli; Franco Trevisani
Journal:  BMC Cancer       Date:  2009-01-27       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.